RxDoctor Payments Data

Calyse Roy

Family · Ashdown, ARNPI 1730630492

Payments from drug & device makers

$2,496in general payments, 2019–2025

Across 153 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$532
  • Takeda Pharmaceuticals U.S.A., Inc.$399
  • Astellas Pharma US Inc$257
  • Boehringer Ingelheim$236
  • Novo Nordisk$177
  • Corium, LLC$167
  • plus $728 from 13 others

What the payments were for

  • Food & beverage$2,29792%
  • Education$1998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,496 in reported general payments places this provider in the 80th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$105,094
JardianceEmpagliflozin21$35,088
OzempicSemaglutide25$31,733
TrulicityDulaglutide28$31,287
EliquisApixaban29$23,295
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$19,131
MyrbetriqMirabegron25$14,487
LinzessLinaclotide21$10,780
XareltoRivaroxaban12$8,060
TrintellixVortioxetine Hydrobromide13$6,557
SymbicortBudesonide/Formoterol Fumarate18$6,235
Janumet XrSitagliptin Phos/Metformin Hcl11$4,738
EdarbyclorAzilsartan Med/Chlorthalidone11$2,583
Gabapentin173$2,430
Pregabalin40$1,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$161$136,381121 claims
Boehringer IngelheimJardiance$236$35,08821 claims
Novo NordiskOzempic$177$31,73325 claims
PfizerEliquis$125$23,29529 claims
Astellas Pharma US IncMyrbetriq$257$14,48725 claims
AbbVieLinzess, Synthroid$532$11,66633 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$399$6,55713 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$32$2,58311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,103 family providers in Arkansas.

Other family in Ashdown

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →